As European markets navigate a landscape marked by mixed economic signals and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to break a two-week losing streak, buoyed by hopes of increased government spending. Amidst this backdrop, growth companies with high insider ownership are often seen as appealing investments due to their potential for strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Elicera Therapeutics (OM:ELIC) | 27.8% | 97.2% |
| Pharma Mar (BME:PHM) | 11.8% | 40.8% |
| Vow (OB:VOW) | 13.1% | 111.2% |
| CD Projekt (WSE:CDR) | 29.7% | 39.1% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
| Devyser Diagnostics (OM:DVYSR) | 35.6% | 94.7% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
| Ortoma (OM:ORT B) | 27.7% | 68.6% |
| Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
| Circus (XTRA:CA1) | 26% | 51.4% |
Here we highlight a subset of our preferred stocks from the screener.
OCI (ENXTAM:OCI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: OCI N.V. is a company that produces and distributes hydrogen-based and natural gas-based products for agricultural, transportation, and industrial sectors, with a market cap of €2.32 billion.
Operations: The company's revenue segments include $976.50 million from Nitrogen EU.
Insider Ownership: 38.9%
OCI N.V. shows potential as a growth company with high insider ownership in Europe. Despite being dropped from the FTSE All-World Index, OCI anticipates profitability and above-average market profit growth over the next three years. Revenue is expected to grow at 14.3% annually, outpacing the Dutch market's 7.9%. The company plans extraordinary distributions of up to $1 billion in Q2 2025, indicating strong shareholder returns despite a forecasted low return on equity at 4%.
- Navigate through the intricacies of OCI with our comprehensive analyst estimates report here.
- Our valuation report here indicates OCI may be overvalued.
BICO Group (OM:BICO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BICO Group AB (publ) is a bioconvergence company operating in North America, Europe, Asia, and internationally with a market cap of SEK2.71 billion.
Operations: The company's revenue is segmented into Bioprinting (SEK369.30 million), Lab Automation (SEK571.60 million), and Life Science Solutions (SEK1.01 billion).
Insider Ownership: 25.2%
BICO Group's revenue is forecast to grow at 7.2% annually, outpacing the Swedish market's 0.8%, with earnings expected to rise by 54.46% per year, signaling strong growth potential despite a volatile share price recently. The company reported significant improvement in net income for Q4 2024, with SEK 346.8 million compared to a prior loss of SEK 561.6 million, though annual sales slightly decreased to SEK 1.95 billion from SEK 2 billion previously.
- Take a closer look at BICO Group's potential here in our earnings growth report.
- The analysis detailed in our BICO Group valuation report hints at an deflated share price compared to its estimated value.
Bonesupport Holding (OM:BONEX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK21.85 billion.
Operations: The company generates revenue primarily from its Pharmaceuticals segment, totaling SEK898.73 million.
Insider Ownership: 10.1%
Bonesupport Holding shows strong growth potential, with earnings forecasted to grow 50.2% annually, surpassing the Swedish market's 9.3%. Recent Q4 results highlight a sales increase to SEK 257.01 million from SEK 172.74 million year-on-year, though net income for the full year decreased to SEK 133.75 million from SEK 245.02 million previously. The company benefits from innovative products like CERAMENT G and V, which demonstrated significant clinical advantages in treating diabetic foot osteomyelitis.
- Get an in-depth perspective on Bonesupport Holding's performance by reading our analyst estimates report here.
- The valuation report we've compiled suggests that Bonesupport Holding's current price could be quite moderate.
Make It Happen
- Dive into all 234 of the Fast Growing European Companies With High Insider Ownership we have identified here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Bonesupport Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com